Genetic Signatures Signs Danish Supply Agreement
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Genetic Signatures Ltd. has signed a supply agreement with Hvidovre Hospital in Denmark for gastrointestinal screening equipment and consumables, which will last for ten years with possible extensions. The agreement includes the adoption of the EasyScreen™ Pan-Enteric assay, which detects a wide range of gastrointestinal pathogens in a single automated workflow. This contract is seen as a significant milestone for Genetic Signatures' growth strategy in Europe and reflects the increasing recognition of its diagnostic technology. The first year of the contract anticipates testing of a substantial number of samples, with expected annual growth in testing volume.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Genetic Signatures' latest callGenetic Signatures (ASX:GSS) Q4 2026 Earnings Call · Replay · Aug 25Read the transcript of Genetic Signatures (ASX:GSS) Q4 2026 Earnings CallGenetic Signatures Ltd. on 6ix
Earlier from Genetic Signatures
- Genetic Signatures Organisational Restructure
- 1H FY26 Results Release
- 1H FY26 Results Presentation
- 1H FY26 Appendix 4D and Half Year Report
- GSS Appoints Anne Lockwood as Interim Managing Director
Later from Genetic Signatures
- Danish Supply Agreement - Additional Information
- BCAL to Acquire Shares in Genetic Signatures
- GSS responds to the BCAL Diagnostics Announcement
- Commercial Testing Commences at Hvidovre Hospital in Denmark
- FY 26 Annual Results and Investor Webinar Notification
Follow Genetic Signatures into a list and get an email when it puts out news.
Follow Genetic Signatures